US equities
|
NVDA
$221.30
▼-3.16%
MU
$914.13
▼-4.10%
AAPL
$342.96
▲+0.50%
AMD
$570.82
▼-5.73%
META
$737.54
▼-3.27%
MSFT
$533.69
▼-1.80%
TSLA
$367.16
▼-2.15%
SNDK
$1,403.34
▼-5.33%
NVDA
$221.30
▼-3.16%
MU
$914.13
▼-4.10%
AAPL
$342.96
▲+0.50%
AMD
$570.82
▼-5.73%
META
$737.54
▼-3.27%
MSFT
$533.69
▼-1.80%
TSLA
$367.16
▼-2.15%
SNDK
$1,403.34
▼-5.33%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biofrontera Inc. - Common Stock
(NQ:
BFRI
)
0.8300
-0.0622 (-6.97%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biofrontera Inc. - Common Stock
< Previous
1
2
3
Next >
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
May 06, 2025
Via
ACCESS Newswire
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
December 03, 2024
Via
ACCESSWIRE
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
November 01, 2024
Via
ACCESSWIRE
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
September 25, 2024
Via
ACCESSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
August 09, 2024
Via
ACCESSWIRE
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
May 15, 2024
Via
ACCESSWIRE
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
March 15, 2024
Via
ACCESSWIRE
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
March 15, 2024
Via
ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
May 06, 2024
Via
ACCESSWIRE
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
May 03, 2024
Via
ACCESSWIRE
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
March 26, 2024
Via
ACCESSWIRE
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
March 08, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Closes on Private Placement Valued at Up to $16M
March 04, 2024
Via
Investor Brand Network
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
Via
ACCESSWIRE
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
October 10, 2023
Via
ACCESSWIRE
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
February 23, 2024
Via
ACCESSWIRE
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
February 20, 2024
Via
ACCESSWIRE
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
February 20, 2024
Via
ACCESSWIRE
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
February 05, 2024
Via
ACCESSWIRE
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
October 04, 2023
Via
ACCESSWIRE
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 11, 2023
Via
ACCESSWIRE
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
August 10, 2023
Via
ACCESSWIRE
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
January 11, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct
November 21, 2023
Via
Investor Brand Network
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
November 03, 2023
Via
ACCESSWIRE
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
October 31, 2023
Via
ACCESSWIRE
Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
October 05, 2023
Via
ACCESSWIRE
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
August 29, 2023
Via
ACCESSWIRE
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
August 28, 2023
Via
ACCESSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
August 04, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
